Abstract 3-Nitrobenzanthrone (3-nitro-7H-benz [de]anthracen-7-one, 3-NBA) is a potent mutagen and suspected human carcinogen identified in diesel exhaust and air pollution. We compared the ability of human hepatic cytosolic samples to catalyze DNA adduct formation by 3-NBA. Using the 32 P-postlabeling method, we found that 12/12 hepatic cytosols activated 3-NBA to form multiple DNA adducts similar to those formed in vivo in rodents. By comparing 3-NBA-DNA adduct formation in the presence of cofactors of NAD(P)H:quinone oxidoreductase (NQO1) and xanthine oxidase, most of the reductive activation of 3-NBA in human hepatic cytosols was attributed to NQO1. Inhibition of adduct formation by dicoumarol, an NQO1 inhibitor, supported this finding and was confirmed with human recombinant NQO1. When cofactors of N,Oacetyltransferases (NAT) and sulfotransferases (SULT) were added to cytosolic samples, 3-NBA-DNA adduct formation increased 10-to 35-fold. Using human recombinant NQO1 and NATs or SULTs, we found that mainly NAT2, followed by SULT1A2, NAT1, and, to a lesser extent, SULT1A1 activate 3-NBA. We also evaluated the role of hepatic NADPH:cytochrome P450 oxidoreductase (POR) in the activation of 3-NBA in vivo by treating hepatic POR-null mice and wild-type littermates i.p. with 0.2 or 2 mg/kg body weight of 3-NBA. No difference in DNA binding was found in any tissue examined (liver, lung, kidney, bladder, and colon) between null and wild-type mice, indicating that 3-NBA is predominantly activated by cytosolic nitroreductases rather than microsomal POR. Collectively, these results show the role of human hepatic NQO1 to reduce 3-NBA to species being further activated by NATs and SULTs. (Cancer Res 2005; 65(7): 2644-52)
Introduction
Environmental factors and individual genetic susceptibility play an important role in many human cancers (1) . Lung cancer is the most common malignant disease worldwide and is the major cause of death from cancer. Tobacco smoking is the overwhelming cause of lung cancer but vehicular exhaust and ambient air pollution are also implicated (2) . Nitro-polycyclic aromatic hydrocarbons (nitro-PAH) are widely distributed environmental pollutants found in vehicular exhaust from diesel and gasoline engines and on the surface of ambient air particulate matter. The increased lung cancer risk after exposure to these environmental sources and the detection of nitro-PAHs in the lungs of nonsmokers with lung cancer has led to considerable interest is assessing their potential cancer risk to humans (3, 4) .
A new member of this group of compounds, 3-nitrobenzanthrone (3-nitro-7H-benz [de] anthracen-7-one, 3-NBA; Scheme 1), was discovered in diesel exhaust and in airborne particulate matter (5, 6) . As a likely consequence of atmospheric washout, 3-NBA has also been detected more recently in surface soil and rainwater (7, 8) .
The main metabolite of 3-NBA, 3-aminobenzanthrone, has been found in urine samples of salt mine workers occupationally exposed to diesel emissions (6) , demonstrating that human exposure to 3-NBA in diesel emissions can be significant and is detectable. 3-NBA is a potent mutagen in the Ames Salmonella typhimurium assay (5) and in the transgenic Muta Mouse assay (9) . It has been shown to be genotoxic in several short-term tests (10) (11) (12) (13) (14) and its genotoxicity has been further documented by the detection of specific DNA adducts formed in vitro as well as in vivo in rodents (9, 10, 12, (14) (15) (16) (17) (18) (19) (20) . Moreover, preliminary data suggest that 3-NBA is carcinogenic to rats (21) .
The detection of specific DNA adducts by 32 P-postlabeling analysis has allowed us to use 3-NBA-DNA binding as an end point for studying the enzymology of the metabolic activation of 3-NBA (9, 12, 14, (16) (17) (18) (19) (20) . Both rat and human microsomal enzymes activate 3-NBA in vitro to form the same DNA adducts found in vivo in rodents (9, 12, 17, 19) . Most of the reductive activation in hepatic microsomes was attributed to P450 oxidoreductase (NADPH:cytochrome P450 oxidoreductase, POR), and this was confirmed with purified and recombinant POR (19) . Buttermilk xanthine oxidase (XO) was also efficient in the reductive activation of 3-NBA (10, 12) . The major DNA adducts of 3-NBA formed after activation with buttermilk XO are products derived from reductive metabolites bound to purine bases (12) . Although the structures of the DNA adducts remain to be characterized, we have shown that the nitroreduction pathway is responsible for the formation of these adducts in various tissues of rats and mice (9, 12, 17, 22) . However, no data are available on the participation of authentic rat or human cytosolic nitroreductases, such as XO and NAD(P)H:quinone oxidoreductase (NQO1).
N-Hydroxyarylamine intermediates formed by nitroreduction can be conjugated by phase II enzymes, such as N,O-acetyltransferases (NAT) and sulfotransferases (SULT), leading to the formation of reactive esters capable of forming DNA adducts (23, 24) . Previous work indicated that N-hydroxy-3-aminobenzanthrone (N-OH-ABA) seems to be the critical intermediate in 3-NBA-DNA adduct formation (12, 14, 17, 22) . Furthermore, we found that Oacetylation by human recombinant NATs as well as O-sulfonation by human recombinant SULTs of N-OH-ABA strongly contribute to the formation of DNA adducts (16, 18) . Because animal enzymes or human recombinant systems may not be ideal models of the catalytic properties of enzymes in human organs, the present study was undertaken to determine the capability of human hepatic cytosols to activate 3-NBA, to identify hepatic cytosolic enzymes involved in DNA adduct formation by 3-NBA, and to evaluate the contribution of hepatic cytosolic and microsomal reductases to the bioactivation of 3-NBA.
Materials and Methods
Chemicals. NADH, NADPH, hypoxanthine, dicoumarol, allopurinol, dAMP, dGMP, buttermilk XO, acetyl-CoA 3V-phosphoadenosine-5V-phosphosulfate (PAPS), menadione (2-methyl-1,4-naphthoquinone), salmon testis, and calf thymus DNA were obtained from Sigma Chemical Co (St. Louis, MO, USA); Sudan I was from BDH (Poole, United Kingdom).
Synthesis of 3-nitrobenzanthrone. 3-NBA was synthesized as described recently (18) and its authenticity was confirmed by UV, electrospray mass spectra, and high field proton nuclear magnetic resonance spectroscopy.
Preparation of cytosols. Cytosolic fractions were isolated from the livers of 10 male Wistar rats, either uninduced or pretreated with Sudan I inducing NQO1 as described (25) . For initial experiments, pooled human hepatic cytosol from Gentest Corp. (Woburn, MA) was used. Cytosolic fractions from livers of 12 human donors were also obtained from Gentest (Table 1) . Cytosolic samples were stored in small aliquots at À80jC for the assays; unused material was discarded after one freeze-thaw cycle. One aliquot of each cytosolic fraction was analyzed for reductase (NQO1 and XO) activities (26, 27) and reanalyzed for NAT and SULT activities by assays described in the protocols of the manufacturer.
Cytosolic incubations. The deaerated and argon-purged incubation mixtures, in a final volume of 750 AL, consisted of 50 mmol/L Tris-HCl buffer (pH 7.4), containing 0.2% Tween 20, cofactors for cytosolic enzymes (1 mmol/L NADH, NADPH, or hypoxanthine; 2 mmol/L acetyl-CoA; 100 Amol/L PAPS), 1 mg of cytosolic protein, 0.3 mmol/L 3-NBA (dissolved in 12.5 AL DMSO), and 1 mg of calf thymus DNA (4 mmol/L dNp). The reaction was initiated by adding 3-NBA. Incubations with rat and human cytosols were carried out at 37jC for 3 hours; the cytosol-mediated 3-NBA-derived DNA adduct formation was linear up to 4 hours. Control incubations were carried out either (a) without activating system (cytosol) or (b) without DNA or (c) without 3-NBA. After the incubation and extraction with ethyl acetate, DNA was isolated from the residual water phase by the phenol-chloroform extraction method as described (28) .
Inhibition studies. Dicoumarol and allopurinol were used to inhibit NQO1 and XO, respectively. Inhibitors dissolved in 7.5 AL methanol, to yield final concentrations of 10 Amol/L, were added to the incubation mixtures as previously reported (26, 27 ). An equal volume of methanol was added to the control incubations.
Enzyme preparations. Rat NQO1 was isolated from hepatic cytosolic fractions from Sudan I-treated rats as described (29 . In incubations testing the activity of purified rat hepatic NQO1, 2 to 30 Ag (0.018-0.09 units) were added and 30 Amol/L 3-NBA were used. The reaction was initiated by adding 3-NBA. All reaction mixtures were incubated at 37jC for 3 hours. In incubations testing the timedependent formation of 3-NBA-DNA adducts mediated by human recombinant NQO1 (0.06 units), incubation times varied between 60 and 240 minutes and 30 Amol/L 3-NBA were used. In control incubations, NQO1 was omitted from the mixtures. In incubations using cytosols of baculovirus-transfected insect cells containing recombinant SULTs and NATs, additionally 10 and 50 Ag of the respective enzyme with the cofactors PAPS or acetyl-CoA were added to the reaction mixture containing human recombinant NQO1. Cytosolic fractions isolated from insect cells, which were not transfected with any human transferases with the respective cofactor, were used as a control. After the incubation, DNA was isolated by the phenolchloroform extraction method as described (28) .
Treatment of hepatic P450 oxidoreductase-null mice and wild-type littermates with 3-nitrobenzanthrone. Male hepatic POR-null mice (30) and wild-type littermates on a C57BL/6 background (25-30 g) were treated with a single dose of 0.2 mg/kg (n = 3) or 2 mg/kg body weight (n = 3) of 3-NBA by i.p. injection. 3-NBA was dissolved in tricaprylin at a concentration of 0.5 mg/mL. Control mice (n = 3) received tricaprylin only. The animals were killed 24 hours after treatment. Five organs (liver, lung, kidney, bladder, and colon) were removed and stored at À80jC until DNA isolation by standard phenol extraction.
Preparation of reference compounds. dAMP and dGMP (4 Amol/mL) were incubated with 3-NBA (0.3 mmol/L) enzymatically activated by buttermilk XO (1 unit/mL) in 50 mmol/L potassium phosphate buffer (pH 7.0) in the presence of 1 mmol/L hypoxanthine as described (10, 12) . Chemical modification of salmon testis DNA with N-OH-ABA was done as follows: 20 mg 3-NBA in 10 mL diglyme was reduced by stirring with 50 AL hydrazine hydrate and 10 mg 5% palladium on charcoal under nitrogen for 30 minutes. The resulting N-OH-ABA solution was decanted and mixed with a solution of 50 mg salmon testis DNA in 50 mL 0.02 mol/L sodium citrate (pH 5.0), and the mixture incubated for 18 hours at 60jC under nitrogen. The mixture was extracted with 20 mL ethyl acetate (3Â) and the DNA precipitated from the aqueous phase with ethanol.
32 P-postlabeling analysis and high-performance liquid chromatography analysis of 32 P-labeled 3V ,5V -deoxyribonucleoside bisphosphate adducts. were done as recently described (16, 17) . DNA adduct spots were numbered as recently reported (16) (17) (18) (19) .
Statistical analysis. Correlation coefficients between the catalytic activities of NQO1 and XO as well as NAT and SULT in human hepatic cytosolic samples and the level of total 3-NBA-DNA adducts formed by the same cytosolic samples were determined by linear regression using Statistical Analysis System software version 6.12. Correlation coefficients were based on a sample size of 12. All of the P values are two-tailed and considered significant at the 0.05 level.
Molecular modeling. Crystallographic coordinates for rat and human NQO1 with bound flavin adenine dinucleotide were obtained from the Protein Data Bank (31) . The coordinates were used without further refinement. The modeling of the binding of 3-NBA to the active site was done with the program Autodock 3.0.3. (32) and Sybyl 6.6.5 (Tripos GmbH, Munich, Germany) by the procedure described (25, 26, 33) . 3-NBA was built up with fragment libraries supplied with the modeling software. The initial structure was first energy minimized to a root-mean-square force of <0.001 with the consistent valence force field (33) .
Results
Activation of 3-nitrobenzanthrone by human and rat hepatic cytosols. We determined the formation of DNA adducts in calf thymus DNA by 3-NBA incubated with human hepatic cytosols or cytosols from the livers of rats, either uninduced or pretreated with Sudan I. Based on previous studies that showed specific sensitivity of arylamine-and nitro-PAH-derived DNA adducts to nuclease P1 treatment, both the butanol extraction and the nuclease P1 digestion enhancement of the 32 P-postlabeling assay were used to analyze 3-NBA-DNA adducts. Hepatic cytosols from rats ( Fig. 1A ) and from humans ( Fig. 1B-D) were capable of activating 3-NBA to form DNA adducts. In each case, 3-NBA induced essentially the same four major DNA adducts (spots 1, 2, 3, and 6) detected after enrichment using nuclease P1 digestion, and a cluster of up to five adducts (spots 1, 2, 3, 4, and 5) detected after enrichment using butanol extraction. These adducts were also observed in liver tissue of 3-NBA-treated rats and mice (9, 12, 17) , and in incubations in vitro using rat and human hepatic microsomes (19) . No DNA adducts were observed in control incubations (data not shown).
Cochromatographic analysis of individual spots on HPLC confirmed that adduct spots 1 to 5 that are formed with human cytosols are derived from 3-NBA by nitroreduction (data not shown). We therefore analyzed which cytosolic reductase is responsible for 3-NBA-DNA adduct formation. As shown in Fig. 2A and C, the formation of 3-NBA-DNA adducts was stimulated by the cofactors of NQO1, NADPH, and NADH (34) , and the cofactor (35) , with both rat and human cytosols. Adduct evels with human cytosols were up to 4.3-, 6.5-, and 1.6-fold higher when NADPH, NADH, or hypoxanthine, respectively, were added to the incubation mixture (Fig. 2C) . With rat cytosols, 3-NBA-DNA adduct formation increased by up to 5.7-, 15.6-, and 19.4-fold after the addition of NADPH, NADH, and hypoxanthine, respectively (Fig 2A) . NQO1 and XO reductively activate 3-NBA in rat cytosol and in human cytosol; however, XO seems to play a minor role in activation of 3-NBA in the human sample. This assumption is also supported by the fact that 3-NBA-DNA adduct formation by human cytosols was remarkably decreased by dicoumarol (70-80% reduction in total DNA binding compared with incubations without dicoumarol), an inhibitor of NQO1 (25, 26) , whereas allopurinol, an inhibitor of XO (25, 26) , showed no effect (data not shown). Cytosols from rats pretreated with Sudan I, an inducer of NQO1 enzyme activity (29) , were very effective in stimulating 3-NBA-DNA adduct formation even without added cofactor. NADPH or NADH increased DNA binding up to 2.8-fold (Fig 2B) .
The influence of NATs and SULTs on the activation of 3-NBA in the pooled human hepatic cytosolic sample was then investigated by adding either acetyl-CoA, the cofactor of NAT (23), or PAPS, the cofactor of SULT (24), into the incubations. As shown in Fig. 2D , the formation of 3-NBA-DNA adducts was stimulated by acetyl-CoA 9.7-fold and by PAPS 35.5-fold over the activity with NADPH. Thus, NATs and SULTs strongly contribute to the metabolic activation of 3-NBA by human cytosol.
Correlation of xanthine oxidase, NAD(P)H:quinone oxidoreductase, N,O-acetyltransferase, and sulfotransferase activities in human hepatic cytosols with DNA adduct formation by 3-nitrobenzanthrone. We compared the ability of 12 human hepatic cytosolic samples to catalyze DNA adduct formation by 3-NBA using NADPH, hypoxanthine, acetyl-CoA, and PAPS as cofactors (Table 1) . Quantitative 32 P-postlabeling analyses, as shown in Table 1 , showed wide variations in DNA binding by 3-NBA in individual cytosolic incubations. On average, the formation of 3-NBA-derived DNA adducts was again increased >6-fold in the presence of NADPH, a cofactor of NQO1, and >2-fold in the presence of hypoxanthine, a cofactor of XO, indicating the major role of NQO1 and a minor role of XO in the bioactivation of 3-NBA in human hepatic cytosol. Here again, acetyl-CoA and particularly PAPS increased 3-NBA-DNA-adduct levels up to 10-fold. No correlation between the activities of NQO1 or XO and the levels of 3-NBA-DNA adducts was observed in these samples. Highly significant correlations were observed between the NAT2 activity and the levels of 3-NBA-derived DNA adducts, whereas no correlation between the activity of SULTs with 7-hydroxycoumarin or NAT1, and 3-NBA-DNA adduct formation was found ( Table 1) .
Activation of 3-nitrobenzanthrone by purified rat and human recombinant NAD(P)H:quinone oxidoreductase. To confirm the role of NQO1 in the activation of 3-NBA, we used human recombinant NQO1 and the NQO1 enzyme purified from livers of rats pretreated with Sudan I (29) . Figure 1E shows that incubations of 3-NBA with DNA and purified rat NQO1 resulted in the formation of the same DNA adduct pattern as with other activating systems and in vivo in rats. Using 0.018 to 0.09 units of rat NQO1, total DNA adduct levels ranged from 15.8 to 23.8 and 16.1 to 35.0 adducts per 10 8 nucleotides after nuclease P1 and butanol enrichment, respectively (data not shown). Similarly, human recombinant NQO1 was efficient at activating 3-NBA (Fig. 1F) . Human NQO1-mediated DNA adduct formation was concentration-dependent up to 15 Amol/L 3-NBA (Fig. 3A) and showed a steep increase between 60 and 240 minutes (Fig. 3B) .
Metabolic activation of 3-nitrobenzanthrone by recombinant human sulfotransferases and N,O-acetyltransferases. To study in more detail the role of individual SULTs and NATs in the bioactivation of 3-NBA by human hepatic cytosols, we used human recombinant enzymes in additional experiments. SULT1A1 is the major SULT expressed in human liver besides SULT2A1 but only low levels of SULT1A2, SULT1A3, and SULT1E1 have been detected in this organ (24) . NAT2 is the major NAT in human liver besides NAT1 (see also NAT activities in Table 1 ). Human recombinant SULTs (SULT1A1, SULT1A2, SULT1A3, SULT1E, or SULT2A1) and NATs (NAT1 and NAT2) were used in incubations together with human recombinant NQO1. DNA adduct formation was observed in all incubations. 3-NBA induced the same adduct pattern as those in human cytosols with PAPS or acetyl-CoA as cofactor ( Fig. 1G and H) . We used 10 and 50 Ag of each cytosolic preparation to account for the amount of protein added that may influence the adduct yield by scavenging reactive metabolites. Indeed, 50 Ag cytosol in the control incubation with acetyl-CoA led to lower adduct yield than 10 Ag (data not shown). In Fig. 3C , the relative DNA binding is shown where the appropriate control was deducted from the incubation with the phase II enzyme and the resulting value divided by the specific activity of the enzyme added. In the case of SULT1A1 and SULT1A2, addition of 50 Ag resulted in >5 times the amount of adducts obtained with 10 Ag, whereas in the case of NAT2 a saturation level was reached. SULT1A2 and especially NAT2 are the most active phase II enzymes promoting 3-NBA-DNA adduct formation after reduction by NQO1. This finding is in line with the results obtained in the correlation analysis for NAT2. None of the other examined SULTs (SULT1A3, SULT1E, and SULT2A1) increased 3-NBA-DNA adduct levels.
The effect of cytosolic and microsomal reductases on activation of 3-nitrobenzanthrone in hepatic P450 oxidoreductase-null mice. Recently, we showed that most of the reductive activation of 3-NBA in human hepatic microsomes is attributed to POR (19) . To evaluate the importance of hepatic POR in the reductive activation of 3-NBA to DNA adducts in vivo compared with cytosolic reduction and conjugation, we treated hepatic PORnull mice (30) and wild-type littermates i.p. with 0.2 or 2 mg/kg body weight of 3-NBA. Essentially, the same DNA adduct patterns as those found in vivo in rats, and in incubations using rat and human hepatic cytosols and microsomes, were observed ( Fig. 1I and J) . No DNA adducts were observed in DNA isolated from tissue of control animals treated with vehicle only (tricaprylin; data not shown). As shown in Fig. 4 , no difference in DNA binding by 3-NBA was found between null and wild-type mice in any of the five tissues examined, indicating that POR does not contribute significantly to the reductive activation of 3-NBA.
Molecular modeling. To examine the molecular basis of the reductive activation of 3-NBA by rat and human NQO1, the binding of 3-NBA to the active center of NQO1 was modeled. The calculated model structure for the human NQO1-3-NBA complex is shown in Fig. 5 . Similarly, the model structure for the rat NQO1-3-NBA complex was calculated (data not shown). It is evident from Fig. 5 that 3 -NBA fits well into the active site of human NQO1, being bound near the isoalloxazine ring of the flavin prosthetic group of the enzyme. This allows an electron transfer during the reductive activation of 3-NBA. The values of the apparent dissociation constant for the rat and human NQO1-3-NBA complexes were calculated to be 0.10 and 0.26 Amol/L, respectively. Reaction of N-hydroxy-3-aminobenzanthrone with DNA. Salmon testis DNA was reacted with N-OH-ABA at 60jC for 18 hours under nitrogen. When DNA digests from this incubation were analyzed by 32 P-postlabeling, essentially the same DNA adduct pattern to those obtained in vivo in rodents, and in incubations using rat and human hepatic cytosols, was observed (Fig. 1K) . HPLC cochromatographic analysis confirmed that all major adducts spots (spots 1, 2, 3, 4, and 5) that are formed with N-OH-ABA are products bound to deoxyadenosine (spots 1 and 2) or deoxyguanosine (spots 3, 4, and 5; data not shown). Thus, these results confirm that N-OH-ABA is the critical intermediate in DNA adduct formation by 3-NBA.
Discussion
In the present study, we have shown that rat and human cytosolic samples are effective in activating 3-NBA leading to the same DNA adduct pattern as those formed in 3-NBA-treated rodents and in incubations using rat and human microsomes (9, 12, 17, 19) . Comparative analyses showed that all major DNA adducts are products derived from reductive metabolites bound to deoxyadenosine (adducts 1 and 2) or deoxyguanosine (adducts 3, 4, and 5). Moreover, adduct 4 is sensitive to digestion with nuclease P1, which is indicative of C-8-deoxyguanosine arylamine-DNA adducts (36) . Furthermore, because we found that all major DNA adducts are detectable after reaction of N-OH-ABA with DNA, we assume that all 3-NBA-DNA adducts are formed by simple nitroreduction. This is in line with previous data indicating that N-OH-ABA is the critical intermediate in 3-NBA-derived DNA adduct formation (14, 17, 18, 22) . However, the low amount of individual DNA adducts recovered from digests of DNA treated with N-OH-ABA prevented further structural characterization of these 3-NBA-DNA adducts. Other synthetic approaches are currently being developed in our laboratory to prepare authentic 3-NBA-DNA adduct standards.
The stimulation of 3-NBA-DNA adduct formation in human hepatic cytosolic samples by NADPH suggested the participation of human NQO1 in the reductive bioactivation of 3-NBA. Inhibition of DNA adduct formation by dicoumarol (25, 26) provided additional evidence for the major role of NQO1, and the utilization of human recombinant NQO1 fully corroborated the capability of this enzyme to activate 3-NBA. Nevertheless, no statistical correlation between the levels of 3-NBA-derived DNA adducts and the NQO1 activities in human cytosolic samples was observed, indicating that additional enzymes (e.g., phase II biotransformation enzymes) may participate in 3-NBA activation. The importance of NQO1 in the reductive activation of nitroaromatics like 3-NBA is consistent with previous reports demonstrating that the enzyme functions efficiently as a nitroreductase of substrates like dinitropyrenes, nitrophenylazaridines, nitrobenzamides, and nitrophenanthrene carboxylic acids (26, 37) . We also showed that isolated rat cytosolic NQO1 efficiently activated 3-NBA. Molecular modeling and docking of 3-NBA to the active centers of rat and human NQO1 protein indicate similarities in 3-NBA binding to both enzymes; calculated apparent dissociation constants (K s ) are of the same order for NQO1 enzymes from both species. However, we found a lower activity of NQO1 isolated from rat hepatic cytosols than of the human recombinant enzyme. The reason for the observed discrepancies might be the different substrate specificities of the recombinant (human) and authentic (rat) enzymes.
It seems that compared with NQO1, human hepatic XO had only minor impact on the activation of 3-NBA to form DNA adducts.
Allopurinol, an inhibitor of XO (25, 26) , did not inhibit DNA adduct formation in pooled human cytosols. However, earlier data had shown that isolated buttermilk XO was an effective activator of 3-NBA (10, 12) , but the enzyme levels needed are unphysiologic and substrate specificities may be different. In rat cytosol, XO had a much greater capacity to activate 3-NBA to form DNA adducts than in human cytosols. This is consistent with a previous observation (15) that the metabolism of 3-NBA in rat alveolar type II cells, involving reduction of 3-NBA to 3-aminobenzanthrone is mediated, at least in part, by XO.
In mammalian cells, both cytosolic and microsomal subfractions contain enzymes that catalyze the reduction of nitroaromatic compounds (25, 26, 28, 37) . In rat and human hepatic microsomes, we have already identified POR as the enzyme activating 3-NBA, generating 3-NBA-DNA adduct profiles identical to those found in liver tissue of 3-NBA-treated rodents (9, 12, 17, 19) . The comparison of 3-NBA-DNA adduct levels formed by human hepatic microsomes (19) and cytosols (present paper) reveals that the cytosolic enzyme systems are much more efficient in the reductive activation of 3-NBA than microsomes. Moreover, the content of cytosolic protein per gram of human liver tissue is about four times higher than that of microsomal protein. Therefore, the importance of the cytosolic enzymes in 3-NBA activation in the organ should be even higher. Nevertheless, in the in vitro experiments, we could not evaluate exactly the significance of microsomal and cytosolic reductases. Therefore, we looked at the in vivo situation. Mice carrying a deletion in the hepatic POR gene (30, 38) , and thus lacking POR and POR-mediated cytochrome P450 activity in the liver, were treated with 3-NBA. No differences in DNA adduct formation by 3-NBA were observed in liver, lung, kidney, bladder, or colon of hepatic POR-null and wild-type mice, emphasizing the major importance of cytosolic nitroreductases and phase II enzymes in the activation of 3-NBA. In contrast, in hepatic POR-null mice treated with 3-aminobenzanthrone, DNA adduct formation in liver DNA was either diminished or significantly reduced, 5 confirming the importance of P450 1A1 and P450 1A2 in the metabolic activation of 3-aminobenzanthrone leading to DNA adducts (22) .
Most tissues contain NQO1 (37) . Expression levels and activities of NQO1 differ considerably among individuals, because the enzyme is influenced by several factors, including smoking, drugs, environmental chemicals, and genetic polymorphisms (39, 40) . Two distinct regulatory elements in the 5V-flanking region of the NQO1 gene, the antioxidant response element and the xenobiotic response element, involving the liganded aromatic hydrocarbon (Ah) receptor, have been shown to regulate NQO1 expression in many cellular systems (37, 41) . Antioxidant response elementmediated NQO1 gene expression is increased by a variety of phenolic antioxidants, tumor promoters, and H 2 O 2 (37, 42) . Human exposure to 3-NBA is thought to primarily occur via the respiratory tract and inhaled particles (e.g., derived from diesel emissions) are able to generate reactive oxygen species like H 2 O 2 (43) . Hence, exposure to particulate matter might enhance 3-NBA activation and increase its genotoxic potential. The xenobiotic response element of NQO1 shares significant homology with the xenobiotic response element of P450 1A1 (44) . Both NQO1 and P450 1A1 genes can be induced by 2,3,7,8-tetrachlorodibenzo [1, 4] dioxin and Sudan I, the latter compound being used in the present study to induce NQO1 in rats (25, 45) .
Using genetically engineered V79 cells expressing human NAT1, NAT2, SULT1A1, or SULT1A2, we previously showed that these enzymes strongly contribute to the metabolic activation of 3-NBA (16, 18) . Moreover, in these cells, 3-NBA induced a dose-dependent increase in the mutation frequency at the hprt locus, 6 indicating that the expression of NATs and SULTs contribute to the mutagenic potency of 3-NBA in mammalian systems. In the present study, we show the participation of authentic human hepatic NATs and SULTs in the bioactivation of 3-NBA leading to DNA adducts. However, whereas a highly significant correlation between the activities of NAT2 and the formation of 3-NBA-DNA adducts was found, no statistically significant correlation with the NAT1 and SULTs activities in the cytosols was observed. Addition of PAPS increased 3-NBA-DNA adduct levels f10-fold in all cytosols, but the SULT activities determined with 7-hydroxycoumarin as substrate showed large variations. No correlation can therefore be calculated because 7-hydroxycoumarin sulfonation does not seem to reflect the activity of SULT in conjugating the product of 3-NBA reduction, N-OH-ABA. It seems, therefore, that the different individual catalytic activities of NQO1, NAT, SULT, and maybe also glutathione transferase contribute collectively to 3-NBA-DNA adduct formation. Using cytosols containing recombinant human NATs or SULTs in incubations with human recombinant NQO1, we showed that mainly NAT2 followed by SULT1A2 and, to a lesser extent SULT1A1 and NAT1, efficiently activate 3-NBA. NAT2 and SULT1A2 are expressed in liver (23, 24) ; more importantly, as recently discussed (16, 18) , NAT1 and NAT2 as well as SULT1A1 and SULT1A2 are expressed in cells of the respiratory tract (46, 47) .
Genetic polymorphisms may contribute to an individual's susceptibility to 3-NBA and could be important determinants of a possible cancer risk of 3-NBA in humans. Thus far, two polymorphisms in the human NQO1 gene have been found in the general population, one of them being associated with an increased risk of urothelial tumors (48) and pediatric leukemia (49) . Human NAT1 and NAT2 are genetically polymorphic, resulting in different activities of the gene product that segregate individuals into slow and rapid acetylator phenotypes (23) . Multiple studies have shown that urinary bladder cancer risk is higher in individuals with slow NAT2 acetylator phenotype, whereas for colon cancer rapid NAT2 acetylator phenotype confers a higher risk (23) . SULT1A1 and SULT1A2 are also polymorphic in humans (24) and are associated with increased cancer risk including lung (50) and esophageal cancer (51) . Thus, genetic polymorphisms in NQO1, NAT, and SULT genes could be important determinants of a possible lung cancer risk from 3-NBA.
In summary, human hepatic cytosols activate the potent mutagen and suspected carcinogen 3-NBA to species forming DNA adducts identical to those formed in vivo in 3-NBA-treated rodents. This is important for the estimation of the 3-NBA genotoxicity (carcinogenicity) to humans. Cytosolic NQO1 is of major importance in catalyzing the first step of the reductive activation of 3-NBA. Additionally, NAT1 and NAT2 as well as SULT1A1 and SULT1A2 expression in cytosols contribute substantially and specifically to the metabolic activation of 3-NBA.
